Goodbye, Ozempic

Earlier this year, my colleague Yasmin Tayag wrote that Ozempic—the diabetes drug that has become a cultural phenomenon in its off-label use for weight-loss—was about to be old news. She was right.

Over the past few days, presentations at the American Diabetes Association meeting in San Diego have delivered a slew of findings that suggest the is already over. Taking its place: a parade of better treatments for obesity. A new, oral form of works about as well as Ozempic or Wegovy, which are injectable versions of the same; so does another pill containing a drug called . New data also hint that shots containing or may end up than semaglutide, and that is perhaps the , with effects approaching those of bariatric surgery. I won’t even bore you with the news about , , and !